We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$545M
Cap. Flow %
13.34%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
26
Allogene Therapeutics
ALLO
$618M
$22.3M 0.55%
4,488,200
– –
LENZ
27
LENZ Therapeutics
LENZ
$162M
$22.2M 0.54%
1,219,778
– –
OVID icon
28
Ovid Therapeutics
OVID
$455M
$20.1M 0.49%
6,117,400
– –
NGM
29
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$16.7M 0.41%
6,435,518
– –
TNGX icon
30
Tango Therapeutics
TNGX
$4.65B
$13.4M 0.33%
4,047,114
-154,300
-4% -$555K
TCRX icon
31
TScan Therapeutics
TCRX
$59.8M
$12.5M 0.31%
+5,000,000
New +$13.4M
GBIO
32
DELISTED
Generation Bio
GBIO
$11.3M 0.28%
204,687
+9,029
+5% +$414K
THRD
33
DELISTED
Third Harmonic Bio
THRD
$10M 0.25%
2,088,780
+286,658
+16% +$1.36M
PHAT icon
34
Phathom Pharmaceuticals
PHAT
$873M
$10M 0.25%
+700,000
New +$8.07M
DYN icon
35
Dyne Therapeutics
DYN
$3.92B
$8.99M 0.22%
798,701
-1,523,683
-66% -$18M
PRME icon
36
Prime Medicine
PRME
$565M
$8.79M 0.22%
600,000
– –
ZNTL icon
37
Zentalis Pharmaceuticals
ZNTL
$364M
$8.46M 0.21%
+300,000
New +$7.2M
JANX icon
38
Janux Therapeutics
JANX
$992M
$5.37M 0.13%
452,590
-3,385,896
-88% -$45.3M
KURA icon
39
CALL
Kura Oncology
KURA
$964M
$5.29M 0.13%
+500,000
New +$5.91M
PRLD icon
40
Prelude Therapeutics
PRLD
$335M
$5.21M 0.13%
+1,157,452
New +$6.92M
PRQR icon
41
ProQR Therapeutics
PRQR
$240M
$4.83M 0.12%
2,980,016
+77,301
+3% +$151K
HOOK
42
DELISTED
HOOKIPA Pharma
HOOK
$4.04M 0.1%
459,502
+212,153
+86% +$2.36M
ALGS icon
43
Aligos Therapeutics
ALGS
$35.5M
$3.83M 0.09%
157,934
– –
ALLK
44
DELISTED
Allakos
ALLK
$3.27M 0.08%
+748,900
New +$3.37M
SYRE icon
45
Spyre Therapeutics
SYRE
$8.7B
$2.25M 0.06%
+200,000
New +$948K
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.73M 0.04%
963,333
– –
TPST icon
47
Tempest Therapeutics
TPST
$15.4M
$1.43M 0.04%
86,418
+7,090
+9% +$178K
FDMT icon
48
4D Molecular Therapeutics
FDMT
$575M
$1.21M 0.03%
+66,978
New +$1.23M
PSTX
49
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.19M 0.03%
676,296
-1,973,704
-74% -$5.04M
NAMSW icon
50
NewAmsterdam Pharma Warrant
NAMSW
$793K 0.02%
66,665
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $545M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.